Additionally, from our personal experience, the administration of a Gln/Arg/HMB product to patients with anastomotic leakage after esophageal cancer surgery shortened the recovery period from anastomotic leakage (13.5 ± 14.3 vs. 35.0 ± 17.4 days, p = 0.043) and maintained serum albumin levels on 14th postoperative day (−1.0 ± 0.32 vs. −1.4 ± 0.49 g/dL, p = 0.047), suggesting its usefulness in wound healing and the maintenance of nutritional status. This evidence concerns the gene ALB and esophageal cancer.